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Summary
Painful	diabetic	neuropathy	(PDN)	is	a	 long-	term	complication	of	diabetes.	Defining	
symptoms	include	mechanical	allodynia	(pain	due	to	light	pressure	or	touch)	and	mor-
phine	hyposensitivity.	In	our	previous	work	using	the	streptozotocin	(STZ)-	diabetic	rat	
model	of	PDN,	morphine	hyposensitivity	developed	in	a	temporal	manner	with	effi-
cacy	abolished	at	3	months	post-	STZ	and	maintained	for	6	months	post-	STZ.	As	this	
time	course	mimicked	 that	 for	 the	 temporal	development	of	hyposensitivity	 to	 the	
pain-	relieving	effects	of	the	furoxan	nitric	oxide	(NO)	donor,	PRG150	(3-	methylfurox
an-	4-	carbaldehyde)	in	STZ-	diabetic	rats,	we	hypothesized	that	progressive	depletion	
of	endogenous	NO	bioactivity	may	underpin	the	temporal	loss	of	morphine	sensitivity	
in	STZ-	diabetic	rats.	Furthermore,	we	hypothesized	that	replenishment	of	NO	bioac-
tivity	may	restore	morphine	sensitivity	in	these	animals.	Diabetes	was	induced	in	male	
Dark	Agouti	rats	by	intravenous	injection	of	STZ	(85	mg/kg).	Diabetes	was	confirmed	
on	day	7	if	blood	glucose	concentrations	were	≥15	mmol/L.	Mechanical	allodynia	was	
fully	developed	in	the	bilateral	hindpaws	by	3	weeks	of	STZ-	diabetes	in	rats	and	this	
was	maintained	for	the	study	duration.	Morphine	hyposensitivity	developed	in	a	tem-
poral	manner	with	efficacy	abolished	by	3	months	post-	STZ.	Administration	of	dietary	
l-	arginine	(NO	precursor)	at	1	g/d	to	STZ-	diabetic	rats	according	to	a	15-	week	pre-
vention	protocol	initiated	at	9	weeks	post-	STZ	prevented	abolition	of	morphine	effi-
cacy.	When	given	as	an	8-	week	intervention	protocol	in	rats	where	morphine	efficacy	
was	abolished,	dietary	l-	arginine	at	1	g/d	progressively	rescued	morphine	efficacy	and	
potency.	Our	findings	implicate	NO	depletion	in	the	development	of	morphine	hypo-
sensitivity	in	STZ-	diabetic	rats.
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1  | INTRODUCTION
Painful	diabetic	neuropathy	(PDN)	is	a	type	of	peripheral	neuropathic	
pain	that	develops	in	the	long	nerves	in	a	“stocking	and	glove”	distri-
bution,	and	that	affects	up	to	20%	of	patients	with	diabetes.1,2	PDN	
symptoms	include	lancinating,	burning	and	shooting	pains	as	well	as	
mechanical	allodynia,	a	type	of	pain	evoked	by	non-	noxious	mechani-
cal	stimuli	such	as	light	pressure	or	touch.1,2	In	our	previous	work,	we	
showed	that	single	bolus	doses	of	the	furoxan	nitric	oxide	(NO)	donor,	
PRG150	 (3-	methylfuroxan-	4-	carbaldehyde),	evoked	dose-	dependent	
pain	relief	in	STZ-	diabetic	rats.	However,	the	efficacious	bolus	doses	
of	PRG150	at	14	and	24	weeks	of	STZ-	diabetes	were	3	to	4	orders	of	
magnitude	higher	than	that	required	at	10	weeks	post-	STZ	or	in	non-	
diabetic control rats.3
In	 other	work	 by	 our	 group	 in	 diabetic	 rats	 assessed	 in	 longi-
tudinal	 studies	 over	 prolonged	 periods,	 morphine	 hyposensitivity	
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developed	 in	 a	 temporal	 manner	 and	was	 fully	 developed	 by	 ap-
proximately	 3	months	 of	 diabetes	with	 it	 being	maintained	 for	 at	
least	6	months.4-6	 Interestingly,	this	time	course	mimicked	that	for	
progressive	development	of	hyposensitivity	to	the	pain-	relieving	ef-
fects	 of	 the	 furoxan	NO	 donor,	 PRG150,	 in	 STZ-	diabetic	 rats3 as 
well	 as	 clinical	 reports	 of	 the	 ineffectiveness	 of	morphine	 for	 the	
symptomatic	 relief	of	PDN.1,2	Together,	our	previous	 findings	sug-
gest	that	temporal	depletion	of	NO	bioactivity	in	advanced	diabetes	
may	have	a	key	role	in	the	pathobiology	of	the	associated	morphine	
hyposensitivity.
Endogenous	NO	is	synthesized	from	the	precursor,	l-	arginine,	by	
3	NO	synthase	 (NOS)	enzymes,	viz	endothelial	NOS,	neuronal	NOS	
and	inducible	NOS.7	Under	normal	conditions	in	vivo,	NO	is	a	highly	
diffusible	gas	with	a	half-	life	of	only	a	few	seconds	that	regulates	many	
physiological	processes.7	However,	after	peripheral	nerve	 injury,	on-
going	ectopic	firing	of	 injured	primary	afferents	 induces	central	sen-
sitization	in	the	dorsal	horn	of	the	spinal	cord	that	is	underpinned	by	
persistent	activation	of	the	N-	methyl-	d-	aspartate	(NMDA)/NOS/NO	
signaling	 cascade	 and	 glial	 cell	 activation,	 to	markedly	 increase	NO	
formation	at	multiple	levels	of	the	somatosensory	nervous	system.8-10 
In	 diabetes,	 there	 is	 increased	 generation	 of	 superoxide	 that	 reacts	
with	elevated	 levels	of	NO	to	 increase	 formation	of	 the	neurotoxin,	
peroxynitrite,	 resulting	 in	nitrooxidative	stress	and	 the	development	
of	PDN.11,12
From	 the	 foregoing,	 we	 developed	 the	 hypothesis	 that	 pro-
gressive	depletion	of	endogenous	NO	bioactivity	may	have	a	key	
role	 in	 the	 temporal	 development	 of	 morphine	 hyposensitivity	
in	 STZ-	diabetic	 rats	 and	 that	 replenishment	 of	 endogenous	NO	
bioactivity	 may	 restore	 morphine	 sensitivity	 in	 these	 animals.	
To	 test	 our	 hypothesis,	 STZ-	diabetic	 rats	were	 administered	 di-
etary l-	arginine	 (NO	precursor)	 at	 1	g/d	 (2.5%	 in	 ground	 rodent	
chow)	according	to	either	a	15-	week	prevention	protocol	(Group	
1)	 commencing	 at	 3	weeks	 prior	 to	 the	 abolition	 morphine	
	efficacy	 	(9-	weeks	 post-	STZ)	 or	 an	 8-	week	 intervention	 protocol	
	commencing	at	14	or	30	weeks	post-	STZ	administration	(Groups	
2	and	3,	respectively).
2  | RESULTS
2.1 | Mechanical hypersensitivity in the hindpaws of 
STZ- diabetic rats
The	 mean	 (±	SEM)	 paw	 withdrawal	 thresholds	 (PWTs)	 in	 the	 bi-
lateral	 hindpaws	 of	 drug-	naïve	 STZ-	diabetic	 Dark	 Agouti	 (DA)	
rats	were	 significantly	 lower	 (P	≤	.05)	 than	 those	 for	 control	 non-	
diabetic	 rats	 (11.9	±	0.2	g).	 Specifically,	 in	 Group	 1	 STZ-	diabetic	
DA	rats	(Figure	1),	the	mean	(±SEM)	PWTs	decreased	significantly	
(F(3,71)	=	265.4,	P	≤	.05;	one-	way	ANOVA	with	Tukey’s	multiple	com-
parisons	test)	from	11.9	(±	0.2)	g	in	non-	diabetic	rats	to	6.8	(±	0.3)	g	
by	9	weeks	post-	STZ	administration.	 In	Group	2	STZ-	diabetic	 rats	
(Figure	1),	 the	mean	 (±	SEM)	 hindpaw	 PWTs	 at	 14	 and	 24	weeks	
post-	STZ	 administration	 were	 significantly	 reduced	 (F(2,11)	=	14.6,	
(P	≤	.05)	one-	way	ANOVA	with	Tukey’s	multiple	comparisons	test)	
to	3.8	(±	0.2)	g	and	3.1	(±	0.3)	g	respectively.	These	data	show	that	
mechanical	allodynia	was	fully	developed	(PWTs	≤	6	g)	for	at	least	
24	weeks	post-	STZ	administration.	 In	Group	3	 rats	 (Figure	1),	 the	
mean	(±	SEM)	hindpaw	PWT	at	24	weeks	post-	STZ	administration	
was	 3.1	 (±	0.1)	g	 which	 differed	 significantly	 (P > .05; unpaired t 
test)	from	that	in	non-	diabetic	rats	at	11.9	(±	0.2)	g.	Overall,	dietary	
l-	arginine	treatment	of	STZ-	diabetic	rats	for	up	to	15	weeks	did	not	
reverse	mechanical	allodynia	in	the	bilateral	hindpaws	(see	details	in	
Supplementary	Results).
F IGURE  1 Schematic	diagram	of	the	3	l-	arginine	dosing	protocols	used	in	the	present	work
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2.2 | Dietary l- arginine prevents loss of morphine 
efficacy in STZ- diabetic rats
2.2.1 | Group 1: l- arginine prevention protocol
The	dose-	response	curve	for	single	subcutaneous	(s.c.)	bolus	doses	
of	morphine	 in	STZ-	diabetic	DA	 rats	 at	9	weeks	post-	STZ	admin-
istration	 is	 shown	 in	 Figure	2.	 The	 corresponding	 mean	 (±	SEM)	
dose	 that	produced	 a	50%	 response	 (ED50)	was	6.1	 (±	0.3)	mg/kg	
in	agreement	with	 that	 for	STZ-	diabetic	DA	rats	at	3	weeks	post-	
STZ	reported	previously	by	our	laboratory.4	Additionally,	the	mean	
(±	SEM)	ED50	 for	 s.c.	morphine	 (7.0	±	0.5	mg/kg)	after	3	weeks	of	
dietary l-	arginine	treatment	(12	weeks	post-	STZ)	did	not	differ	sig-
nificantly	(F(2,54)	=	2.9,	P	>	.05;	one-	way	ANOVA	with	Tukey’s	multi-
ple	comparison	test)	from	that	determined	in	Group	1	STZ-	diabetic	
DA	rats	just	prior	to	initiation	of	the	dietary	l- arginine intervention 
at	 9	weeks	 post-	STZ	 (Figure	2).	 Thus,	 administration	 of	 dietary	 l- 
arginine	for	as	little	as	3	weeks	prevented	the	abolition	of	morphine	
efficacy	 (Figure	2)	 that	otherwise	occurs	at	12	weeks	post-	STZ	as	
previously reported by our laboratory.4,5	After	15	weeks	of	dietary	
l-	arginine	treatment	in	the	same	animals	(24	weeks	post-	STZ),	acute	
s.c.	morphine	efficacy	was	maintained	 (Figure	2)	 in	 contrast	 to	 its	
abolition	 in	STZ-	diabetic	DA	rats	at	24	weeks	post-	STZ	that	were	
fed	a	standard	rodent	chow	diet.4	Specifically,	after	15	weeks	of	di-
etary l-	arginine,	the	s.c.	morphine	dose-	response	curve	was	shifted	
to	 the	 left	 (Figure	2)	 such	 that	 the	 mean	 (±	SEM)	 ED50 was 5.0 
(±	0.9)	mg/kg	(Figure	2)	c.f.	7.0	(±	0.5)	mg/kg	in	the	same	animals	at	
12	weeks	post-	STZ	administration	ie,	after	3	weeks	treatment	with	
dietary l- arginine.
2.3 | Dietary l- arginine restores morphine 
efficacy and potency in STZ- diabetic rats
2.3.1 | Group 2: l- arginine early 
intervention protocol
Administration	of	 the	s.c.	morphine	ED50	 (6.1	mg/kg)	determined	at	
9	weeks	post-	STZ	in	Group	1	rats	(Figure	2),	to	Group	2	diabetic	rats	
at	14	weeks	post-	STZ,	showed	that	the	anti-	allodynic	efficacy	of	mor-
phine	was	abolished	in	these	animals	(Figure	3).	Specifically,	the	mean	
(±	SEM)	extent	and	duration	of	anti-	allodynia	(percent	maximum	pos-
sible	effect	area	under	the	curve;	%Maximum	Possible	Effect	[MPE]	
AUC)	was	only	5.2	(±	2.5)	%MPE.h	(Figure	3).	However,	after	4	weeks	
of	the	dietary	l-	arginine	intervention	in	these	animals	(18	weeks	post-	
STZ),	morphine	efficacy	was	 restored	 (Figure	3)	 such	 that	 the	mean	
(±	SEM)	%MPE	AUC	for	a	single	s.c.	dose	of	morphine	at	6.1	mg/kg	
was	109.8	(±	28.6)	%MPE.h	(Figure	3).	Four	weeks	later	after	8	weeks	
of	the	dietary	l-	arginine	intervention	(22	weeks	post-	STZ),	morphine	
efficacy	was	not	only	 retained	 in	 these	animals	 (Figure	3)	but	 there	
was	a	significant	increase	in	the	potency	of	single	s.c.	bolus	doses	of	
morphine	at	6.1	mg/kg	(F(2,11) = 14.5; P	≤	.05;	one-	way	ANOVA	with	
Tukey’s	multiple	 comparison	 test)	 (Figure	3).	Additionally,	 the	mean	
(±	SEM)	%MPE	 AUC	was	 149.5	 (±	9.5)	 %MPE.h	which	 did	 not	 dif-
fer	 (F(3,16)	=	11.5,	 P >	.05;	 one-	way	 ANOVA	 with	 Tukey’s	 multiple	
F IGURE  2 Dietary l-	arginine	(1	g/d	mixed	in	ground	rodent	
chow)	administered	as	a	prevention	protocol	prevented	temporal	
development	of	morphine	hyposensitivity	in	adult	male	STZ-	diabetic	
Dark	Agouti	(DA)	rats.	Specifically,	there	was	a	2-	fold	rightward	shift	
in	the	dose-	response	curve	for	single	s.c.	bolus	doses	of	morphine	
at	( )	9	weeks	post-	STZ	administration	relative	to	that	for	non-	
diabetic	male	DA	rats.	Administration	of	dietary	l-	arginine	for	
3	weeks	(12	weeks	post-	STZ)	prevented	the	abolition	of	morphine	
efficacy	that	otherwise	occurred	in	similar	animals.4,5 Administration 
of	the	dietary	l-	arginine	intervention	for	15	weeks	in	the	same	STZ-	
diabetic	animals	not	only	prevented	the	development	of	morphine	
hyposensitivity,	but	it	increased	morphine	potency	by	~50%.	( )	
Non-	diabetic;	( )	9	weeks	post-	STZ;	pre	l-	Arg;	( )	12	weeks	post-	
STZ;	3	weeks	l-	Arg;	( )	24	weeks	post-	STZ;	15	weeks	l- Arg
F IGURE  3 Administration	of	dietary	l- arginine according to 
an	intervention	protocol	rescued	morphine	efficacy	and	potency	
in	adult	male	STZ-	diabetic	DA	rats	exhibiting	marked	morphine	
hyposensitivity	at	14	weeks	post-	STZ.	Specifically,	mean	(±	SEM)	
response	(%	maximum	possible	effect,	%MPE)	vs	time	curves	for	
single	s.c.	bolus	doses	of	morphine	at	6.1	mg/kg	administered	to	
STZ-	diabetic	rats	at	14	weeks	post-	STZ	and	then	at	4	and	8	weeks	
after	initiation	of	a	dietary	l-	arginine	intervention	(18	and	22	weeks	
post-	STZ	respectively)	in	the	same	animals	showed	restoration	of	
morphine	efficacy	and	a	progressive	increase	in	potency	over	the	
8-	week	l-	arginine	treatment	period.	( )	14	weeks	post-	STZ;	( )	
18	weeks	post-	STZ	with	4	weeks	l-	Arg;	( )	22	weeks	post-	STZ	with	
8	weeks	l- Arg
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comparison	test)	from	that	for	s.c.	morphine	at	6.1	mg/kg	in	opioid-	
naïve	non-	diabetic	control	rats	(136.9	±	16.1%MPE.h).
2.3.2 | Group 3: l- arginine late intervention protocol
In	STZ-	diabetic	DA	rats	where	morphine	efficacy	had	been	abolished	
since	12	weeks	post-	STZ	administration,4	an	8-	week	dietary	l- arginine 
intervention	 at	 1	g/d	 commencing	 at	 30	weeks	 post-	STZ	 (Figure	1),	
resulted	 in	 restoration	 of	 morphine	 efficacy	 (Figure	4).	 Specifically,	
after	 4	weeks	 of	 dietary	 l-	arginine,	 the	 mean	 (±	SEM)	 %MPE	 AUC	
value	 evoked	 by	 an	 s.c.	 bolus	 dose	 of	 morphine	 at	 6.1	mg/kg	 was	
62.2	 (±	15.8)	 %MPE.h	 (Figure	4)	 which	 did	 not	 differ	 significantly	
(F(4,23)	=	31.1,	 P >	.05;	 one-	way	 ANOVA	with	 Tukey’s	 multiple	 com-
parison	 test)	 from	 that	 (63.6	 ±	7.4%MPE.h)	 evoked	 in	 Group	 1	 dia-
betic	 rats	at	9	weeks	post-	STZ	and	fed	a	standard	rodent	chow	diet	
(Figure	2).	Continuation	of	the	late	dietary	l-	arginine	intervention	for	
a	further	4	weeks	to	8	weeks	in	the	same	animals	(30-	38	weeks	post-	
STZ)	(Figure	4)	resulted	in	a	significant	increase	(F(4,23)	=	31.1,	P	≤	.05;	
one-	way	ANOVA	with	Tukey’s	multiple	comparison	test)	in	morphine’s	
anti-	allodynic	potency	(Figure	4).	Specifically,	the	mean	(±	SEM)	%MPE	
AUC	evoked	by	a	single	s.c.	bolus	dose	of	morphine	at	6.1	mg/kg	was	
117.1	(±	15.4)	%MPE-	h	which	was	approximately	2-	fold	larger	than	the	
respective	mean	(±	SEM)	%MPE	AUC	value	after	4	weeks	of	the	late	
dietary l-	arginine	intervention	in	the	same	animals	(Figure	4).
2.3.3 | Dietary l- arginine: No effect on morphine 
efficacy or potency in control non- diabetic rats
Mean	(±	SEM)	food	intake	for	l-	arginine	treated	STZ-	diabetic	rats	was	
43.2	(±	0.2)	g/d	whereas	control	non-	diabetic	rats	treated	with	dietary	
l-	arginine	consumed	20.5	(±	0.7)	g	of	food	per	day.	Thus,	in	order	to	
give	 comparable	 doses	 of	 l-	arginine	 to	 both	 STZ-	diabetic	 and	non-	
diabetic	weight-	matched	control	rats,	the	concentration	of	l- arginine 
in	 the	 ground	 rodent	 chow	was	 2-	fold	 higher	 for	 non-	diabetic	 rats	
at	5%	c.f.	2.5%	 for	STZ-	diabetic	animals.	For	non-	diabetic	male	DA	
rats,	 the	mean	 (±	SEM)	ED50	 at	 3.0	 (±	0.2	mg/kg)	 for	 the	 antinocic-
eption	 (%MPE)	dose-	response	curve	 (Figure	5)	evoked	by	single	s.c.	
bolus	doses	of	morphine	did	not	differ	significantly	(P > .05; unpaired t 
test)	from	that	(2.5	±	0.2	mg/kg)	for	non-	diabetic	male	DA	rats	admin-
istered l-	arginine	 (1	g/d)	 for	1	week	prior	 to	antinociceptive	 testing	
(Figure	5).	Thus,	 chronic	administration	of	dietary	 l- arginine did not 
alter	morphine	antinociception	in	opioid-	naïve	non-	diabetic	male	DA	
rats	(Figure	5).
2.4 | General health
Following	induction	of	diabetes	with	STZ,	there	was	a	12%-	13%	de-
crease	 in	mean	 (±	SEM)	 body	weight	 (see	 details	 in	 Supplementary	
Results	online)	and	there	was	a	marked	increase	in	blood	glucose	con-
centrations	(from	6	to	>20	mmol/L)	(Supplementary	Results).	Dietary	
administration	of	 l-	arginine	 at	1	g/d	mixed	 in	 rodent	 chow	 to	STZ-	
diabetic	rats	for	up	to	15	weeks	did	not	adversely	alter	body	weight	
(P >	.05)	 and	 it	 had	 no	 significant	 effect	 on	 elevated	 blood	 glucose	
concentrations	(P >	.05)	(see	details	in	Supplementary	Results).
3  | DISCUSSION
Our	findings	show	for	the	first	time	that	dietary	administration	of	the	
endogenous	NO	substrate,	 l-	arginine	at	1	g/d	according	 to	either	a	
15-	week	 prevention	 protocol	 (Figure	1)	 or	 an	 8-	week	 intervention	
protocol	 (Figure	1)	 in	 STZ-	diabetic	 rats	 modulated	 the	 extent	 and	
F IGURE  4 Dietary l- arginine administered as an intervention 
protocol	rescued	morphine	efficacy	and	potency	in	adult	male	STZ-	
diabetic	DA	rats	exhibiting	abolition	of	morphine	efficacy	at	24	weeks	
post-	STZ.	Specifically,	mean	(±	SEM)	response	(%	maximum	possible	
effect,	%MPE)	vs	time	curves	for	single	s.c.	bolus	doses	of	morphine	
at	6.1	mg/kg	administered	to	STZ-	diabetic	rats	at	24	weeks	post-	STZ	
and	then	again	at	4	and	8	weeks	after	l- arginine treatment initiation 
(34	and	38	weeks	post-	STZ	respectively)	showed	restoration	of	
morphine	efficacy	and	a	progressive	increase	in	potency	over	the	
8-	week	l-	arginine	treatment	period.	( )	24	weeks	post-	STZ;	( )	
34	weeks	post-	STZ	with	4	weeks	l-	Arg;	( )	38	weeks	post-	STZ	with	
8	weeks	l- Arg
F IGURE  5 Administration	of	dietary	l- arginine to non- diabetic 
adult	male	DA	rats	for	1	week	did	not	alter	morphine	sensitivity	
relative	to	that	for	similar	animals	fed	standard	rodent	chow.	
Specifically,	the	dose-	response	curve	for	single	s.c.	bolus	doses	
of	morphine	in	groups	of	non-	diabetic	male	Dark	Agouti	rats	
administered	either	(i)	rodent	chow	supplemented	with	5%	l- arginine 
for	1	week	or	(ii)	standard	rodent	chow	for	1	week,	did	not	differ	
significantly	(P > .05; unpaired t	test).	( )	No	l-	Arg;	( )	1	week	
l- Arg
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duration	of	pain	relief	evoked	by	single	s.c.	bolus	doses	of	morphine	
in	these	animals	(Figs	2-4).	Specifically,	15	weeks	of	dietary	l- arginine 
given	according	to	a	prevention	protocol	initiated	at	9	weeks	post-	STZ	
administration	 in	 rats,	 prevented	 the	abolition	of	morphine	efficacy	
that	otherwise	occurred	at	12	weeks	post-	STZ	 (Figure	2)	 in	compa-
rable	rats	fed	a	standard	rodent	chow	diet.4,5	Not	only	was	morphine	
efficacy	maintained	in	these	animals,	but	the	potency	of	morphine	did	
not	differ	significantly	(P > .05)	from	that	in	the	same	animals	prior	to	
commencement	of	the	dietary	l-	arginine	treatment	(Figure	2).
Intriguingly,	 initiation	 of	 a	 dietary	 l-	arginine	 (1	g/d)	 intervention	
after	morphine	efficacy	had	been	abolished	 in	STZ-	diabetic	 rats	 (ie,	
at	 14	weeks	 post-	STZ	 for	Group	 2;	 Figure	1),	 progressively	 rescued	
morphine	 efficacy	 and	 potency	 over	 an	 8-	week	 treatment	 period	
(Figure	3).	Administration	of	the	same	dietary	l-	arginine	regimen	(1	g/d	
for	8	weeks)	to	STZ-	diabetic	rats	commencing	at	30	weeks	post-	STZ,	
also	progressively	restored	morphine	efficacy	and	potency	in	the	bilat-
eral	hindpaws	of	these	animals	(Figure	3).
In	 weight-	matched	 control,	 non-	diabetic	 rats,	 dietary	 l- arginine 
at	1	g/d	had	no	significant	 (P > .05)	effect	on	morphine	potency	rel-
ative	 to	 that	 for	 control	 non-	diabetic	 rats	 fed	 a	 standard	 rat	 chow	
diet	 (Figure	5).	Our	 findings	 are	 aligned	with	 previous	work	by	oth-
ers13	whereby	a	single	intraperitoneal	(ip)	bolus	dose	of	l- arginine at 
200	mg/kg	given	10	minutes	prior	to	morphine	had	no	significant	ef-
fect	on	levels	of	antinociception	in	mice.
The	restoration	of	morphine	efficacy	in	STZ-	diabetic	rats	adminis-
tered	the	l-	arginine	dietary	intervention	for	8	weeks	occurred	despite	
the	ongoing	neuropathic	pain	state	that	remained	unaltered	in	these	
animals	during	 the	8	weeks	of	 l-	arginine	 treatment.	The	mechanism	
by	which	l-	arginine	progressively	rescued	morphine	efficacy	and	po-
tency	over	the	8-	week	treatment	period	in	STZ-	diabetic	rats	without	
altering	 the	underlying	peripheral	neuropathic	pain	state,	 is	unclear.	
However,	NO	formed	 from	the	dietary	 l-	arginine,	may	have	attenu-
ated	perineurial	hypoxia	and	the	associated	oxidative	stress,	as	well	as	
reducing	otherwise	elevated	levels	of	diacylglycerol	and	activated	pro-
tein	kinase	C	(PKC),	that	are	produced	as	a	consequence	of	persistent	
hyperglycaemia	in	diabetes.14,15	Of	particular	importance	to	the	pres-
ent	work,	 PKC	mechanisms	 are	 implicated	 in	 desensitization	 of	 the	
opioid receptor16-22	as	well	as	the	development	of	diabetic	complica-
tions.16	A	role	for	PKC	in	the	development	of	opioid	hyposensitivity	in	
diabetes	is	supported	by	observation	that	supraspinal	pretreatment	of	
STZ-	diabetic	rats	with	the	PKC	inhibitor,	calphostin	C,	prevented	the	
development	of	opioid	hyposensitivity.23,24
In	 recent	 work	 by	 others	 in	 STZ-	diabetic	 rats	 exhibiting	 opioid	
hyposensitivity,	MOP	receptor	immunoreactive	primary	sensory	neu-
rons	were	 co-	localized	with	 activated	PKC	 isoforms	 as	well	 as	with	
the	 receptor	 for	 advanced	 glycation	 end	 products	 (RAGE).16	 Using	
a	 range	of	measures	 including	 administration	of	 a	 selective	PKC	 in-
hibitor,	 intrathecal	RAGE	siRNA,	or	 inhibition	of	 advanced	glycation	
end	product	(AGE)	formation	to	prevent	both	RAGE-	dependent	PKC	
activation	and	desensitization	of	the	MOP	receptor,	opioid	analgesic	
efficacy	was	 restored.16	 In	 other	work	 in	 rats	with	 advanced	diabe-
tes	at	12	weeks	post-	STZ,	the	inhibitory	effects	of	intraplantar	bolus	
doses	of	morphine	on	capsaicin-	induced	nocifensive	behaviour	were	
impaired.25	Also,	 there	was	 a	markedly	 reduced	 inhibitory	 effect	 of	
morphine	on	capsaicin-	induced	TRPV1	current	in	DRG	neurons	from	
these	animals.25	These	changes	were	associated	with	a	 loss	of	func-
tional	MOP	but	not	TRPV1	receptors	in	primary	sensory	neurons	with	
all	 changes	 reversed	 by	 intrathecal	 infusion	 of	 nerve	 growth	 factor	
(NGF).25	NO	plays	 a	 role	 in	NGF-	mediated	 neurotrophic	 responses.	
Hence,	it	is	plausible	that	chronic	dietary	administration	of	l- arginine 
in	STZ-	diabetic	rats	to	replenish	in	vivo	NO	bioactivity	and	modulate	
NGF-	TrkA	signaling	pathways,26	underpins	the	rescue	of	morphine	an-
algesic	efficacy	in	advanced	diabetes	herein.
In	 the	Zucker	Diabetic	Fatty	 rat	model	of	Type	2	diabetes,	mor-
phine	hyposensitivity	in	animals	with	advanced	diabetes	at	29	weeks	
of	 age,	was	 underpinned	by	 reduced	MOP	 receptor	 function	 in	 the	
spinal	cord	that	appeared	to	be	due	to	reduced	basal	G-	protein	activ-
ity.6	In	other	work	in	rats	with	advanced	diabetes	(12	weeks	post-	STZ	
administration),	hyposensitivity	to	the	pain-	relieving	effects	of	single	
intrathecal	 (i.t.)	 bolus	 doses	 of	 the	MOP	 receptor	 agonist,	 fentanyl,	
was	accompanied	by	a	reduction	in	MOP	immunoreactivity	in	small	di-
ameter	sensory	neurons,	a	reduction	in	membrane-	bound	MOP	bind-
ing	sites	and	impaired	MOP	receptor	G-	protein	coupling	in	the	dorsal	
horn	of	 the	spinal	cord.27	Pretreatment	with	 intrathecal	bolus	doses	
of	NGF	reversed	these	changes	and	rescued	opioid	responsiveness.25
Although	 dietary	 supplementation	with	 l- arginine restored mor-
phine	 efficacy	 and	 potency	 in	 STZ-	diabetic	 rats	 herein,	 this	 treat-
ment	had	only	a	minor	effect	on	baseline	PWTs.	These	 findings	are	
in	contrast	to	work	by	others	where	administration	of	l- arginine as a 
prevention	protocol	in	the	drinking	water	(2.6	g/L	for	3	weeks;	water	
consumption	276	mL/d)	prevented	the	development	of	both	mechan-
ical	 and	 thermal	 hypersensitivities	 in	 the	 hindpaws	 of	 STZ-	diabetic	
rats.28	 This	 difference	 may	 be	 because	 l- arginine treatment com-
menced	at	the	time	of	diabetes	onset	rather	than	at	9,	14	or	30	weeks	
post-	STZ	administration	as	was	done	in	the	present	work.
As l-	arginine	has	the	potential	to	stimulate	hormonal	secretion	in-
cluding	that	of	growth	hormone,	glucagon,	prolactin	and	insulin,29 we 
assessed	the	effect	of	chronic	dietary	l- arginine on blood glucose levels 
in	rats	with	advanced	STZ-	induced	diabetes.	Importantly,	we	show	that	
irrespective	 of	when	 the	 dietary	 l- arginine intervention was initiated 
in	the	interval	9-	30	weeks	post-	STZ	administration,	it	did	not	alter	the	
markedly	elevated	blood	glucose	levels	(>20	mmol/L)	in	these	animals	
(Supplementary	 Results).	 Our	 findings	 are	 aligned	 with	 other	 work	
whereby	 intravenous	 injection	of	a	bolus	dose	of	l-	arginine	 (150	mg/
kg)	followed	by	chronic	infusion	(10	mg/kg	per	minute	for	60	minutes),	
did	not	 significantly	alter	 (P >	.05)	blood	glucose	 levels	 in	either	non-	
diabetic	or	STZ-	diabetic	rats.30	Furthermore,	chronic	l- arginine adminis-
tration	in	the	drinking	water	at	1.25	mg/mL	for	4	weeks	commencing	at	
12	weeks	post-	STZ	administration	or	at	1.0	mg/mL	for	12	weeks	after	
diabetes induction31,32	did	not	significantly	alter	(P > .05)	hyperglycae-
mia	in	these	animals,	mirroring	the	profoundly	elevated	blood	glucose	
levels	measured	in	STZ-	diabetic	rats	herein.
Irrespective	of	the	cellular	mechanisms	involved	in	the	restoration	
of	morphine	efficacy	in	rats	with	advanced	STZ-	diabetes	and	given	di-
etary l-	arginine	treatment	at	1	g/d	for	either	15	weeks	according	to	a	
prevention	protocol	or	8	weeks	according	to	an	intervention	protocol,	
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our	 findings	 suggest	 that	 NO	 donors	 may	 restore	 opioid	 analgesic	
efficacy	in	patients	with	advanced	diabetes.	If	so,	 it	may	be	possible	
to	 provide	 improved	 pain	 relief	 in	 diabetic	 patients	 whose	 PDN	 is	
poorly relieved by clinically available drug treatments recommended 
by	 the	Neuropathic	Pain	Special	 Interest	Group	of	 the	 International	
Association	for	the	Study	of	Pain,	such	as	the	gabapentinoids	and	the	
tricyclic antidepressants.33
In	 summary,	 our	 findings	 are	 the	 first	 to	 provide	 in	 vivo	 ev-
idence	 linking	 depletion	 of	 NO	 bioactivity	with	 the	 development	
of	morphine	hyposensitivity	in	the	STZ-	diabetic	rat	model	of	PDN.	
Specifically,	 treatment	of	STZ-	diabetic	 rats	with	dietary	 l- arginine 
at	1	g/d	for	15	weeks	according	to	a	prevention	protocol	prevented	
the	abolition	of	morphine	efficacy	that	otherwise	occurred	in	STZ-	
diabetic	 rats	 at	 12	weeks	 post-	STZ	 administration.	 Additionally,	
treatment	 of	 STZ-	diabetic	 rats	 that	were	 insensitive	 to	 the	 pain-	
relieving	effects	of	single	s.c.	bolus	doses	of	morphine,	with	dietary	
l-	arginine	at	1	g/d	for	8	weeks	according	to	an	intervention	proto-
col	progressively	 rescued	morphine	efficacy	and	potency	 in	 these	
animals	without	significantly	altering	the	underlying	peripheral	neu-
ropathic	pain	state.
4  | MATERIALS AND METHODS
4.1 | In vivo experimentation
4.1.1 | Animals
Ethics	 approval	 was	 from	 the	 Animal	 Ethics	 Committee	 of	 The	
University	 of	 Queensland	 (Brisbane,	 Australia).	 Male	 DA	 rats	 were	
purchased	from	the	Central	Animal	Breeding	House,	The	University	
of	Queensland.	Rats	were	housed	in	pairs	in	a	temperature	controlled	
room	 (21	±	2°C;	mean	±	SD)	with	a	12	h/12	h	 light/dark	cycle.	Rats	
had	 free	 access	 to	 rodent	 chow	 and	water,	 and	were	 acclimatized	
prior	to	initiation	of	experimentation.
4.2 | Reagents and materials
l-	arginine	 hydrochloride,	 streptozotocin,	 citric	 acid	 and	 trisodium	
citrate	were	from	Sigma	Aldrich	 (Sydney,	Australia).	Morphine	hy-
drochloride	 was	 from	 the	 Pharmacy	 Department,	 Royal	 Brisbane	
and	Women’s	Hospital	(Brisbane,	Australia).	Sodium	benzylpenicillin	
(Benpen)	vials	containing	600	mg	of	powder,	ketamine	hydrochlo-
ride	 (Ketamav-	100)	 vials	 (100	mg/mL)	 and	 xylazine	 hydrochloride	
(Ilium	Xylazil-	20)	vials	(20	mg/mL)	were	from	Abbott	Australasia	Pty	
Ltd	(Sydney,	Australia).	Sodium	chloride	ampoules	were	from	Delta	
West	Pty.	Ltd.	(Perth,	Australia).	Single	lumen	polyethylene	tubing	
(0.5	mm	 internal	 diameter)	was	 from	Critchley	Electrical	 Products	
Pty.	Ltd.	(Auburn,	Australia).	Blood	glucose	testing	strips	(Glucostix)	
were	 from	 The	 University	 of	 Queensland	 Campus	 Pharmacy	
(Brisbane,	 Australia)	 and	 a	 glucometer	 Precision	 Q.I.D	 was	 from	
Medisense	 Australia	 Pty	 Ltd	 (Melbourne,	 Australia).	 Medical	
grade CO2 and O2	were	purchased	from	BOC	Gases	Australia	Ltd.	
(Brisbane,	Australia).
4.3 | Induction of diabetes with Streptozotocin (STZ)
Anaesthesia	was	induced	with	a	mixture	of	ketamine	(100	mg/kg,	ip)	
and	 xylazine	 (16	mg/kg,	 ip)	 to	 facilitate	 insertion	 of	 a	 polyethylene	
cannula	(pre-	filled	with	0.1	mL	of	sterile	saline)	into	the	right	common	
jugular	 vein.	 Cannulae	 were	 tested	 for	 correct	 placement	 by	 with-
drawing	 a	 small	 amount	 of	 blood.	Diabetes	was	 induced	 in	 rats	 by	
injection	of	STZ	(85	mg/kg	in	0.1	mol/L	citrate	buffer	at	pH	4.5)	via	
the	jugular	vein	cannula.3-5	Benzylpenicillin	(60	mg	s.c.)	was	adminis-
tered and rats were monitored during surgical recovery. Diabetes was 
confirmed	on	day	7	post-	STZ	 in	 individual	 rats	 if	daily	water	 intake	
was	≥100	mL	and	blood	glucose	levels	(BGLs)	were	≥15	mmol/L.	Non-	
diabetic	rats	were	used	in	the	control	experiments.
4.4 | l- arginine dietary administration
A	 group	 of	 control	 non-	diabetic	 rats	 received	 dietary	 l- arginine at 
1	g/d	(5%	mixed	with	ground	rodent	chow)	for	7	days.	This	l- arginine 
dose	 was	 used	 previously	 by	 others	 in	 hypertensive	 non-	diabetic	
rats.34	A	2-	fold	 lower	 concentration	of	 l-	arginine	 (2.5%	mixed	with	
ground	 rodent	 chow)	 was	 used	 in	 STZ-	diabetic	 rats	 because	 their	
mean	(±	SEM)	food	consumption	was	2-	fold	higher	at	43.2	(±	0.2)	g/d	
compared	with	20.5	(±	0.7)	g/d	for	the	non-	diabetic	group.
4.5 | Dosing solutions and dose administration
A	stock	 solution	of	morphine	 (45	mg/mL	as	 the	 free	base	 in	 sterile	
saline)	was	prepared	 for	 s.c.	 bolus	dose	administration	and	aliquots	
were	frozen	at	approximately	−20°C	until	 required.	On	each	dosing	
occasion,	an	aliquot	was	thawed	and	serially	diluted	with	sterile	saline	
to	produce	the	required	dosing	solution.	Rats	received	a	single	s.c.	in-
jection	(100	μL)	of	morphine	into	the	scruff	of	the	neck,	using	a	250	μL	
Hamilton	syringe.
4.6 | Treatment groups
This	study	comprised	3	groups	of	STZ-	diabetic	DA	rats	and	1	group	
of	non-	diabetic	DA	rats.	Morphine	bolus	dose	administration	was	ac-
cording	to	a	“washout”	protocol	with	4	days	of	washout	between	suc-
cessive	doses	and	each	rat	received	a	maximum	of	3	doses.
4.6.1 | Group 1 STZ- diabetic rats: l- arginine 
prevention protocol
Group	1	DA	 rats	 (n	=	25;	 256	±	3.6	g,	mean	±	SEM)	 received	 an	 in-
travenous	 dose	 of	 STZ	 (85	mg/kg)	 and	 were	 studied	 longitudinally	
over	 a	 6-	month	 period.	 For	 each	 testing	 session,	 rats	 received	 sin-
gle	s.c.	doses	of	morphine.	 Individual	animals	 received	one	of	 three	
bolus	doses	of	morphine	(Figure	1)	to	produce	dose-	response	curves	
at	9,	12	and	24	weeks	post-	STZ.	PWTs	were	measured	in	the	bilateral	
hindpaws	at	regular	intervals	over	a	3-	hour	post-	dosing	period	using	
Von	 Frey	 filaments.	 At	 9	weeks	 post-	STZ	 in	 Group	 1	 STZ-	diabetic	
rats,	dietary	l-	arginine	at	1	g/d	mixed	with	ground	rodent	chow	was	
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initiated	and	continued	until	study	completion	at	24	weeks	post-	STZ	
administration.
4.6.2 | Group 2 STZ- diabetic rats: l- arginine early 
intervention protocol
Group	2	STZ-	diabetic	DA	rats	(n	=	17,	239.7	±	4.9	g,	mean	±	SEM)	
received	an	intravenous	injection	of	STZ	(85	mg/kg)	and	were	stud-
ied	 longitudinally	 over	 a	 6-	month	 period.	 Individual	 rats	 (n	=	6)	
received	 the	 ED50	 dose	 of	 s.c.	 morphine	 (6.1	mg/kg)	 determined	
in	 Group	 1	 rats	 at	 9	weeks	 post-	STZ	 to	 evaluate	 the	 acute	 anti-	
allodynic	 responses	 at	14,	18	and	22	weeks	post-	STZ	administra-
tion	 (Figure	2).	 PWTs	were	measured	 in	 the	bilateral	 hindpaws	at	
regular	 intervals	over	a	3-	hour	post-	dosing	period	as	for	Group	1.	
At	 14	weeks	 post-	STZ	 administration,	 an	 l- arginine dietary inter-
vention	at	1	g/d	mixed	with	ground	rodent	chow	was	initiated	and	
continued	for	8	weeks	(Figure	2).
4.6.3 | Group 3 STZ- diabetic rats: l- arginine late 
intervention protocol
Group	 3	 STZ-	diabetic	 DA	 rats	 (n	=	6,	 228.8	±	4.2	g,	 mean	±	SEM)	
were	a	sub-	group	of	the	same	rats	used	by	Nielsen	et	al.4	These	had	
previously	received	single	s.c.	bolus	doses	of	morphine	at	3,	9,	12	and	
24	weeks	post-	STZ	administration.4	Commencing	at	30	weeks	post-	
STZ,	 these	 animals	 received	 dietary	 l-	arginine	 mixed	 with	 ground	
rodent	chow	at	1	g/d	for	8	weeks	(Figure	3).	After	4	and	8	weeks	of	
dietary l-	arginine,	rats	received	a	single	bolus	dose	of	s.c.	morphine	
at	6.1	mg/k	(ED50	in	STZ-	diabetic	rats	at	9	weeks	post-	STZ	in	Group	
1).	PWTs	were	measured	in	the	bilateral	hindpaws	at	regular	intervals	
over	a	3-	hour	post-	dosing	period	as	for	Groups	1	and	2.
4.6.4 | Control non- diabetic rats
A	group	of	opioid-	naïve,	non-	diabetic	DA	rats	(n	=	18;	215.0	±	2.0	g,	
mean	±	SEM)	 received	 one	 of	 three	 bolus	 doses	 (Figure	4)	 of	 s.c.	
morphine.	 PWTs	were	measured	 in	 the	 bilateral	 hindpaws	 at	 regu-
lar	 intervals	over	a	3-	hour	post-	dosing	period.	Opioid-	naïve	control	
DA	rats	that	had	received	dietary	l-	arginine	at	1	g/d	mixed	in	ground	
rodent	chow	for	1-	week	(n	=	18;	236.8	±	2.5	g,	mean	±	SEM)	also	re-
ceived	a	single	s.c.	bolus	dose	of	morphine	and	underwent	antinoci-
ceptive	testing	(Figure	4).	As	STZ-	diabetic	rats	eat	twice	as	much	as	
non-	diabetic	rats,	the	concentration	of	l-	arginine	mixed	with	ground	
rodent	chow	administered	to	control	non-	diabetic	rats	was	doubled	to	
5%	to	ensure	that	l-	arginine	intake	was	similar	between	STZ-	diabetic	
rats	and	the	control	non-	diabetic	rats.
4.7 | Assessment of paw withdrawal thresholds 
in the bilateral hindpaws
Mechanical	allodynia	 in	 the	bilateral	hindpaws,	a	defining	symptom	
of	 neuropathic	 pain,	 was	 assessed	 using	 calibrated	 Von	 Frey	 fila-
ments	(2-	20	g).	In	brief,	rats	were	placed	individually	into	wire	mesh	
cages	(20	cm	×	20	cm	×	20	cm)	and	allowed	to	acclimatize.	Von	Frey	
filaments	were	used	to	measure	the	lowest	mechanical	threshold	to	
evoke	a	brisk	hindpaw	withdrawal	reflex	starting	with	the	2	g	filament.	
The	absence	of	a	response	after	5	seconds	prompted	application	of	
the	next	 filament	of	 increasing	 force.	A	score	of	20	g	was	given	 to	
animals	that	did	not	respond	to	any	of	the	filaments.	Pre-	drug	(mor-
phine)	paw	withdrawal	thresholds	(PWTs)	were	the	mean	of	3	read-
ings	taken	~5	minutes	apart.	Assessment	of	bilateral	hindpaw	PWTs	
was	determined	pre-	dose	and	at	the	following	times	post-	morphine	
administration:	0.25,	0.5,	0.75,	1.0,	1.5,	2.0	and	3.0	hours.
4.8 | Data analysis
The	Von	Frey	scores	 for	 individual	 rats	were	converted	 to	 the	per-
centage	of	the	Maximum	Possible	Effect	(%MPE),	using	the	following	
formula:	
	where	maximum	threshold	=	20	g.
%MPE	vs	time	curves	were	constructed	for	individual	rats.	The	area	
under	the	%MPE	vs	time	curve	(%MPE	AUC	value;	%MPE.h)	was	calcu-
lated	using	trapezoidal	 integration.	The	mean	(±	SEM)	percentage	maxi-
mum	AUC	(%Max	AUC)	for	each	morphine	dose	was	plotted	vs	the	log	
dose to produce dose- response curves. ED50	doses	(mean	±	SEM)	were	
estimated	using	non-	linear	regression	of	the	%Max	AUC	vs	log	dose	values	
as	implemented	in	the	GraphPad	Prism	(v	6.0)	statistical	analysis	package.
4.9 | Statistical analysis
A	one-	way	ANOVA	with	Tukey’s	multiple	comparison	test	as	imple-
mented	in	the	GraphPad	Prism	statistical	analysis	package	was	used	to	
assess	differences	in	body	weights,	blood	glucose	levels	and	bilateral	
hindpaw	PWTs	between	the	treatment	groups.	One-	way	ANOVA	with	
Tukey’s	multiple	comparison	test	was	also	used	to	compare	the	ED50 
values	for	morphine	for	the	various	treatment	groups	in	STZ-	diabetic	
rats.	Unpaired	 t tests were used to compare various parameters in 
non- diabetic rats administered dietary l-	arginine	at	1	g/d	for	1	week	
compared	with	similar	animals	fed	standard	rodent	chow.	The	statisti-
cal	significance	criterion	was	P < .05.	For	statistical	comparisons	using	
one-	way	ANOVA,	F values are reported as F(df	of	treatment,	residual).
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